The tentative negotiated agreement, which includes the family’s and company’s contributions, would be $10 billion to $12 billion. It would not be a cash payout; instead most of the money would come from restructuring the company under a Chapter 11 bankruptcy filing.
The discussions about a settlement have been going on for months, according to the report.
Purdue Pharma and the Sacklers are looking to settle more than 2,000 claims that the company used deceptive marketing and sales practices to boost prescriptions of OxyContin, the Times reported. Plaintiffs argue the tactics contributed to the national opioid epidemic.
The Sackler family and Purdue Pharma have denied the allegations.
More articles on pharmacy:
FDA approves AbbVie’s $59K rheumatoid arthritis drug
Teva launches generic version of EpiPen for kids
American Regent boosted price of essential hospital product by 1,300%
